This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on July 28, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Notice of Intent to Sole Source the Procurement of Weekly Delivery of Turkey, Chicken, Guinea Pig, and Horse Red Blood Cells

Closed

75D301-26-R-73503Federal

Submission Closed08/04/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

Federal

Custom Homing Peptide Synthesis and AAV Capsid ModificationThis subcontract for the Department of Veterans Affairs, specifically supporting the Harry S Truman Memorial Veterans Hospital, involves the synthesis of targeting peptides and genetic engineering services. The scope of work includes designing homing peptides, modifying AAV capsid genomes for peptide display, and producing modified viral vector prototypes. These activities are to be conducted using molecular cloning tools and DNA/RNA synthesis platforms within BSL-2 facilities. The selected provider must hold BSL-2 certification to deliver the required modified AAV vector constructs and synthesized peptide sequences. Performance of the contract will take place in Columbia, Missouri, under NAICS code 325414. The solicitation was posted on October 21, 2026, with a response deadline of November 4, 2026.

POSTED

DEADLINE

Brand Name - Dectomax (Doramectin) 500mL Injectable Solution

Solicitation # 12639527Q0009

Solicitation 12639527Q0009 is a combined synopsis and request for quotation issued by the Department of Agriculture for the procurement of 2,400 bottles of Dectomax (Doramectin) 500mL Injectable Solution. This firm-fixed-price acquisition is a total small business set-aside under NAICS code 325414 and is intended to support the USDA Cattle Fever Tick Eradication Program in Texas. The required items must be new and the exact brand name specified from Zoetis Inc., as alternate or substitute products are deemed technically unacceptable. All deliverables must be shipped F.O.B. destination to Laredo, Texas, within 30 days of the contract award. Award will be made based on best value, specifically to the lowest priced, technically acceptable offer with an acceptable or neutral past performance rating. To be considered technically acceptable, offerors must provide sufficient documentation, such as manufacturer quotes or datasheets, to verify the product and ensure a clear, auditable paper trail of traceability back to the original equipment manufacturer. Additionally, contractors must furnish a Certificate of Conformance per FAR 52.246-15. Quotations must remain firm for 90 calendar days, and the deadline for submission is October 30, 2026.

POSTED

DEADLINE

Supplier of Pressure Sensitive Adhesive Tape (NSN 7510-01-358-8770)This subcontract involves the supply of Type I Code M pressure sensitive adhesive tape to prime contractors supporting Department of Defense DLA supply contracts. The material must strictly adhere to NSN 7510-01-358-8770 and RA001 technical specifications. The scope of work requires the delivery of eight rolls of mercury-free tape, each maintaining a minimum shelf life of 24 months. Compliance with federal standards is mandatory, including packaging per MIL-STD-2073-1E, marking per MIL-STD-129, and hazardous material labeling according to the Hazard Communication Standard. Deliveries are to be made FOB Origin to DLA Distribution San Joaquin in Tracy, California. The opportunity is categorized under NAICS code 325414.

CONSTRUCTION & EQUIPMENT T & IFO EQ

POSTED

DEADLINE

Supply of Defibrinated Rabbit BloodThis subcontract involves the supply of defibrinated rabbit blood to prime contractors supporting projects for the Defense Health Agency within the Department of Defense. The scope of work includes the collection of rabbit blood, the defibrination process to meet specific requirements, and the bottling of the product into 50ml units. To ensure quality and traceability, the provider must generate lot numbers and product data sheets for every unit produced. The execution of this contract requires the use of biological processing equipment and laboratory-grade bottling facilities. The total deliverable consists of 48 units of defibrinated rabbit blood per period of performance, with the place of performance located in Silver Spring, Maryland. This opportunity falls under NAICS code 325414 and is associated with a response deadline of October 23, 2026.

Defense Health Agency (dha)

POSTED

DEADLINE

PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood

Solicitation # PANDHA-26-P-0000_046638

The Defense Health Agency Contracting Activity, acting on behalf of the Walter Reed Army Institute of Research, intends to award a sole source contract to Lampire Biological Labs, Inc. under FAR 6.302 for the procurement of defibrinated rabbit blood. The requirement is categorized under NAICS code 325414 for Biological Product Manufacturing. The contract structure consists of a base year followed by four one-year option periods, with a delivery requirement of 48 units per period of performance, where each unit is defined as one 50ml bottle. The contractor must ensure each unit is provided with a lot number and an associated product data sheet. Strict packaging and shipping standards are required to prevent leaks, spillage, and damage, while maintaining a temperature range of 2 to 8 degrees Celsius upon arrival at the destination in Silver Spring, Maryland. This procurement is being handled as a presolicitation notice of intent to sole source, with a response deadline for capability statements set for October 23, 2026.

Defense Health Agency (dha)

POSTED

DEADLINE

VAC to Finished Vaccine ConversionThis subcontract involves the conversion of Government-owned Vaccine Antigen Concentrate into final-use Foot and Mouth Disease vaccine doses for prime contractors supporting USDA APHIS projects. The scope of work includes formulating the concentrate into a usable vaccine, performing filling and packaging within cleanroom facilities, and conducting essential final potency and efficacy testing. The project is managed under the Department of Agriculture and will be performed in Ames, Iowa. To be eligible, the contractor must hold a USDA Veterinary Biological Product License. The solicitation was posted on October 1, 2026, with a response deadline of November 10, 2026, falling under NAICS code 325414.

POSTED

DEADLINE

FMD Vaccine Antigen Concentrate (VAC) ProductionThis subcontract for the Department of Agriculture involves the production of Foot and Mouth Disease Vaccine Antigen Concentrates for prime contractors on USDA APHIS projects. The scope of work includes the purification and concentration of VAC serials, which are produced by engineering Master Seed Viruses or utilizing field strains in accordance with 9 CFR Parts 113 and 114. To qualify, the provider must possess a USDA Veterinary Biological Product License and provide propagation cell line data approved by the Center for Veterinary Biologics. The final deliverables are purified and concentrated FMD VAC serials, with performance taking place in Ames, Iowa. The response deadline for this opportunity is November 10, 2026.

POSTED

DEADLINE

Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)

Solicitation # 12639527R0001

Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.

POSTED

DEADLINE

Antithrombin III Procurement

Solicitation # CBP-CON-00260

The National Blood Authority is seeking tenders for the procurement of an Antithrombin III product under solicitation number CBP-CON-00260. While the agency currently maintains supply arrangements for Thrombotrol through the National Fractionation Agreement for Australia, this request for tender opens the process for the provision of these essential medical supplies. Interested parties must submit their responses by the deadline of November 20, 2026. All inquiries and submissions should be directed to the CBP Procurement Team via the provided contact email. Further detailed specifications and requirements are contained within the official request for tender documentation.

National Blood Authority

POSTED

DEADLINE

Proteomics and Protein Expression AnalysisThe Proteomics and Protein Expression Analysis subcontract supports National Institutes of Health projects focused on identifying biomarkers related to substance exposure and brain development. The selected provider will perform protein identification and quantification for prime contractors using a variety of high-sensitivity methods, including mass spectrometry, ELISA, Western blotting, and protein-protein interaction assays via LC-MS/MS. To ensure the integrity of the results, the performing laboratory must adhere to ISO/IEC 17025 quality standards. The primary deliverables for this engagement consist of detailed quantitative biomarker reports and comprehensive protein expression profiles. This effort falls under NAICS code 325414 and is managed through the Department of Health and Human Services.

National Institutes Of Health

POSTED

DEADLINE

Medical Diagnostic Test Kit SupplyThe Defense Logistics Agency under the Department of Defense has issued a subcontract for the supply of 100 E. coli detection test kits. These diagnostic kits must strictly adhere to FDA regulations, specific shelf-life requirements, and Department of Defense medical packaging standards to ensure quality and viability. Classified under NAICS code 325414, this procurement focuses on the delivery of specialized medical diagnostic tools. The contract was posted on August 11, 2026, and is managed through the DLA's acquisition systems to support military medical readiness.

Defense Logistics Agency

POSTED

DEADLINE

Medical Supply Procurement – Petrolatum GauzeThis subcontract with the Defense Logistics Agency under the Department of Defense involves the manufacture or supply of 27 units of petrolatum gauze, identified by NSN 6510-01-112-6414. The procurement falls under NAICS code 325414 and requires all units to meet strict military medical standards. Key delivery requirements include a minimum shelf life of 36 months, with a mandate that the time elapsed from manufacture to delivery does not exceed five months. The contract was posted on August 10, 2026.

Defense Logistics Agency

POSTED

2 months ago

DEADLINE

N/A

AI Contract Overview

The Centers for Disease Control and Prevention intends to award a sole-source firm fixed price contract to Lampire Biological Laboratories for the weekly delivery of turkey, chicken, guinea pig, and horse red blood cells used in hemagglutination inhibition assays critical to influenza surveillance. These red blood cells must meet exacting biological performance standards to ensure compatibility with validated CDC assay protocols and to maintain the integrity of longitudinal data used for FluView reporting and vaccine strain selection. Lampire is the only known manufacturer whose products have been proven to consistently support these assays, and switching to an alternative supplier would require extensive and time-consuming validation to confirm equivalency, risking disruption to ongoing surveillance efforts. No competitive solicitation will be issued for this requirement, as the government has determined that Lampire Biological Laboratories is the sole source capable of meeting its operational needs without compromising data continuity. This notice serves solely to assess whether any other responsible sources could meet the technical and performance criteria, with any responses due by August 4, 2026, at 3:00 p.m. Eastern Time to the Contract Specialist at cbp0@cdc.gov. The procurement under NAICS code 325414 and PSC 6505 is managed by the CDC Office of Acquisition Services in Atlanta, Georgia, and all feedback received will be evaluated solely to determine whether a competitive process is warranted, with the final decision resting entirely at the government’s discretion.

General Info

CDC to solely procure red blood cells from Lampire for influenza surveillance, no competition due to unique performance requirements.

Agency

Department Of Health And Human Services → CDC Office Of Acquisition Services

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

GA, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedJul 28

Combined Synopsis

Response DeadlineAug 4

Deadline has passed

Submission Closed

08/04/2026, 07:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

Contacts2 people available

OfficeATLANTA, GA, 30333, USA

Organization / AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

Office AddressATLANTA, GA, 30333, USA

Contacts

ADA TORRES VEGA

contact@example.gov

Liubov Kriel

contact@example.gov

Full Description

This is a combined synopsis/solicitation for a sole-source requirement.

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract for weekly delivery of turkey, chicken, guinea pig, and horse red blood cells (RBCs) under product service code (PSC) 6505-Drugs and Biologicals and North American Industry Classification System (NAICS) code) 325414-Blood derivatives manufacturing, manufactured by Lampire Biological Laboratories for use in hemagglutination inhibition (HI) assays performed by the CDC- National Center for Immunization and Respiratory Diseases (NCIRD)-Influenza Division. The required capability is the ability to consistently provide RBCs with the biological performance characteristics necessary to support validated HI assay methods and maintain continuity of CDC influenza surveillance data.

The required RBCs must be produced using manufacturing, donor sourcing, collection, processing, quality control, and storage practices that yield consistent hemagglutination performance across all required animal species. The products must demonstrate compatibility with the Influenza Division's validated assay protocols and preserve comparability with historical antigenic characterization data used for routine influenza surveillance, FluView reporting, and influenza vaccine strain selection.

Lampire Biological Laboratories is the only known manufacturer whose turkey, chicken, guinea pig, and horse RBCs have been validated for these established CDC HI assay protocols and have consistently demonstrated the performance characteristics required to maintain continuity of longitudinal surveillance data. Use of RBCs from another manufacturer would require extensive validation to establish equivalency and assess impacts on assay performance and historical data comparability. Until such equivalency is demonstrated, no other manufacturer's products will satisfy the Government's minimum requirement to support uninterrupted, consistent influenza surveillance.

No solicitation will be published for this requirement. This notice is issued solely to determine whether there are any responsible sources capable of meeting the Government's requirements.

This notice of intent is not a request for competitive quotations; however, all capability statements, or responses received within five (5) days of the issuance of this notice shall be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

Any capability statement, or response should be emailed to the Contract Specialist, Ada Torres Vega, at cbp0@cdc.gov no later than August 4, 2026, at 3:00 p.m. Eastern Time (ET).